1Drossman DA. The functional gastrointestinal disorders and the Rome Ⅲ process [J]. Gastroenterol, 2006, 130: 1377 -1390.
2Miwa H. Why dyspepsia can occur without organic disease: pathogenesis and management of functional dyspepsia [J]. J Gastroenterol, 2012,47: 862-871.
3Rothstein RD. Gastrointestinal motility disorders in diabetes mellitus[J]. Am J Gastroenterol, 1990,85:782-785.
4Tornhlom H, Lindberg G. A 21 st century look at the spectrum of gastrointestinal motility disorders. What is dysmotility; what is functional? [J]. Gastroenterol Clin North Am, 2011, 40: 715- 723.
5Chen SL. A review of drug therapy for functional dyspepsia [J]. J Dig Dis ,2013 ,14 :623-625.
6Lacy BE, Talley NJ, Locke GR 3rd, et al. Review article: current treatment options and management of functional dyspepsia [J]. Aliment Pharmacol Ther ,2012,36: 3-15.
7Jorge JX, Almeida CC, Borges CI, et al. Effects of gastroesophageal reflux on esophageal motility [J]. Rom J Intern Med,2012,50: 233-239.
8Cho YK, Choi MG, Lim CH, et al. Impaired esophageal bolus transit in patients with gastroesophageal reflux disease and abnormal esophageal Acid exposure[J]. Gut Liver,2012,6: 440- 445.
9Ho SC, Chang CS, Wu CY, et al. Ineffective esophageal motility is a primary motility disorder in gastroesophageal reflux disease [J]. Dig Dis Sci,2002,47: 652-656.
10Rubenstein JH, Morgenstern H, McConell D, et al. Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett' s esophagus [J]. Gastroenterol,2013 ,145: 1237-1244. el-5.
